<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01619878</url>
  </required_header>
  <id_info>
    <org_study_id>CCOA566B2306</org_study_id>
    <secondary_id>2011-005852-33</secondary_id>
    <secondary_id>2011-005858-33</secondary_id>
    <nct_id>NCT01619878</nct_id>
  </id_info>
  <brief_title>Efficacy, Safety and Pharmacokinetics of Artemether-lumefantrine Dispersible Tablet in the Treatment of Malaria in Infants &lt; 5 kg</brief_title>
  <official_title>An Open-label, Single-arm Study to Evaluate the Efficacy, Safety and PK of Artemether-lumefantrine Dispersible Tablet in the Treatment of Acute Uncomplicated Plasmodium Falciparum Malaria in Infants &lt;5 kg Body Weight</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medicines for Malaria Venture</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      The purpose of the study is to obtain efficacy, safety and pharmacokinetic (PK) data
      following treatment with artemether-lumefantrine dispersible tablet in infants &lt; 5 kg of body
      weight (BW) with uncomplicated falciparum malaria.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Polymerase Chain Reaction (PCR) Corrected 28 Day Parasitological Cure Rate</measure>
    <time_frame>28 days</time_frame>
    <description>Number of participants with clearance of asexual parasites by day 7 after initiating study treatment without recrudescence at day 28, corrected for re-infection by Polymerase Chain Reaction (PCR) assay.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Polymerase Chain Reaction (PCR) Corrected Parasitological Cure Rate at Day 14 and 42</measure>
    <time_frame>Day 14 and 42</time_frame>
    <description>Number of participants with clearance of asexual parasites by day 7 after initiating study treatment without recrudescence at day 14 and day 42, corrected for re-infection by Polymerase Chain Reaction (PCR) assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Parasitological Uncorrected Cure Rate at Day 3, 7, 14, 28 and 42</measure>
    <time_frame>Day 3, 7, 14, 28 and 42</time_frame>
    <description>Number of patients with clearance of asexual parasites at day 3, 7, 14, 28 and 42 after initiating study treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change of Parasite Count From Baseline at 24 Hours</measure>
    <time_frame>baseline, 24 hours</time_frame>
    <description>Percent change of parasite count from baseline at 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Parasitaemia at 48 Hours After Treatment Initiation Greater Than at Baseline</measure>
    <time_frame>48 hours</time_frame>
    <description>Number of participants with parasite density at 48 hours after treatment initiation greater than parasite density at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Parasitaemia at 72 Hours After Treatment Initiation Greater Than or Equal to 25 Percent of Count at Baseline</measure>
    <time_frame>72 hours</time_frame>
    <description>Number of participants with parasite density at 72 hours after treatment initiation greater than or equal to 25 percent of parasite density at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Parasite Clearance (PCT)</measure>
    <time_frame>Up to 7 days</time_frame>
    <description>Time from first dose until first total and continued disappearance of asexual parasite forms which remains at least a further 48 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Fever Clearance (FCT)</measure>
    <time_frame>Up to 7 days</time_frame>
    <description>Time from first dose to the first time the axillary body temperature decreased below and remained below 37.5° C for at least 48 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Gametocyte Clearance (GCT)</measure>
    <time_frame>Up to 7 days</time_frame>
    <description>Time from first dose until first total and continued disappearance of gametocytes which remains at least a further 48 hours.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Acute Uncomplicated Falciparum Malaria</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One Artemether-lumefantrine (COA566) dispersible tablet taken orally twice a day during 3 days.
Infants age &gt;28 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Artemether-lumefantrine (COA566)</intervention_name>
    <description>One dispersible tablet taken orally twice a day during 3 days.</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <other_name>Artemether-lumefantrine, COA566</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Neonates / infants

          -  Body weight &lt; 5 kg

          -  In cohort 1, infants aged &gt; 28 days; in cohort 2, neonates of a term age 0 to ≤ 28
             days

          -  Microscopically confirmed diagnosis of acute uncomplicated Plasmodium falciparum
             malaria or mixed infections with an asexual Plasmodium falciparum parasitaemia of &gt;
             1,000 and &lt; 100,000 parasites/µL

        Exclusion Criteria:

          -  Presence of severe malaria (according to World Health Organization definition)

          -  Presence of the following signs of a critical condition: apnea-bradycardia, sustained
             bradycardia, tachycardia, desaturation, hypotension, hypothermia; or other severely
             deteriorated general condition (based on IMCI criteria in sick infants)

          -  Presence of any clinically significant neurological condition

          -  Presence of clinically significant abnormality of the hepatic and renal systems

          -  Patients who sustained a significant blood volume loss (&gt; 3% of calculated blood
             volume) in the past 30 days

          -  Patients unable to swallow or whose drinking is impaired

          -  Family history of congenital prolongation of the QTc interval or sudden death or with
             any other clinical condition known to be associated with prolongation of the QTc
             interval such as history of symptomatic cardiac arrhythmias, with clinically relevant
             bradycardia or with severe cardiac disease

          -  Disturbances of electrolyte balance (e.g. hypokalaemia or hypomagnesaemia)

          -  Presence of any age-adjusted clinically or hematologically relevant laboratory and
             blood chemistry abnormalities

          -  Other protocol-defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cotonou</city>
        <zip>01 BP 107</zip>
        <country>Benin</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Cotonou</city>
        <country>Benin</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Burkina Faso</city>
        <zip>2208</zip>
        <country>Burkina Faso</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Ouagadougou</city>
        <country>Burkina Faso</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Kinshasa</city>
        <country>Congo</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Calabar</city>
        <country>Nigeria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Lome</city>
        <country>Togo</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Benin</country>
    <country>Burkina Faso</country>
    <country>Congo</country>
    <country>Nigeria</country>
    <country>Togo</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 12, 2012</study_first_submitted>
  <study_first_submitted_qc>June 13, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 14, 2012</study_first_posted>
  <results_first_submitted>May 11, 2015</results_first_submitted>
  <results_first_submitted_qc>June 1, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 17, 2015</results_first_posted>
  <last_update_submitted>June 1, 2015</last_update_submitted>
  <last_update_submitted_qc>June 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>plasmodium</keyword>
  <keyword>P. falciparum</keyword>
  <keyword>malaria</keyword>
  <keyword>infant</keyword>
  <keyword>neonate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
    <mesh_term>Malaria, Falciparum</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lumefantrine</mesh_term>
    <mesh_term>Artemether</mesh_term>
    <mesh_term>Artemisinins</mesh_term>
    <mesh_term>Artemether-lumefantrine combination</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The participant that did not complete in the &quot;6 week follow-up phase&quot; was also included in &quot;Follow-up at 12 Months of Age&quot; and was lost to follow-up</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Cohort 1</title>
          <description>One Artemether-lumefantrine (COA566) dispersible tablet taken orally twice a day during 3 days.
Infants age &gt;28 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>6 Week Follow-up Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Follow-up at 12 Months of Age</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cohort 1</title>
          <description>One Artemether-lumefantrine (COA566) dispersible tablet taken orally twice a day during 3 days.
Infants age &gt;28 days.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="99.1" spread="51.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Polymerase Chain Reaction (PCR) Corrected 28 Day Parasitological Cure Rate</title>
        <description>Number of participants with clearance of asexual parasites by day 7 after initiating study treatment without recrudescence at day 28, corrected for re-infection by Polymerase Chain Reaction (PCR) assay.</description>
        <time_frame>28 days</time_frame>
        <population>Full analysis set (FAS) – all subjects receiving at least one dose of study drug and who are confirmed to have P. falciparum malaria at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>One Artemether-lumefantrine (COA566) dispersible tablet taken orally twice a day during 3 days.
Infants age &gt;28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Polymerase Chain Reaction (PCR) Corrected 28 Day Parasitological Cure Rate</title>
          <description>Number of participants with clearance of asexual parasites by day 7 after initiating study treatment without recrudescence at day 28, corrected for re-infection by Polymerase Chain Reaction (PCR) assay.</description>
          <population>Full analysis set (FAS) – all subjects receiving at least one dose of study drug and who are confirmed to have P. falciparum malaria at baseline.</population>
          <units>number of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Polymerase Chain Reaction (PCR) Corrected Parasitological Cure Rate at Day 14 and 42</title>
        <description>Number of participants with clearance of asexual parasites by day 7 after initiating study treatment without recrudescence at day 14 and day 42, corrected for re-infection by Polymerase Chain Reaction (PCR) assay.</description>
        <time_frame>Day 14 and 42</time_frame>
        <population>Full analysis set (FAS) – all subjects receiving at least one dose of study drug and who are confirmed to have P. falciparum malaria at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>One Artemether-lumefantrine (COA566) dispersible tablet taken orally twice a day during 3 days.
Infants age &gt;28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Polymerase Chain Reaction (PCR) Corrected Parasitological Cure Rate at Day 14 and 42</title>
          <description>Number of participants with clearance of asexual parasites by day 7 after initiating study treatment without recrudescence at day 14 and day 42, corrected for re-infection by Polymerase Chain Reaction (PCR) assay.</description>
          <population>Full analysis set (FAS) – all subjects receiving at least one dose of study drug and who are confirmed to have P. falciparum malaria at baseline.</population>
          <units>Number of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Parasitological Uncorrected Cure Rate at Day 3, 7, 14, 28 and 42</title>
        <description>Number of patients with clearance of asexual parasites at day 3, 7, 14, 28 and 42 after initiating study treatment.</description>
        <time_frame>Day 3, 7, 14, 28 and 42</time_frame>
        <population>Full analysis set (FAS) – all subjects receiving at least one dose of study drug and who are confirmed to have P. falciparum malaria at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>One Artemether-lumefantrine (COA566) dispersible tablet taken orally twice a day during 3 days.
Infants age &gt;28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Parasitological Uncorrected Cure Rate at Day 3, 7, 14, 28 and 42</title>
          <description>Number of patients with clearance of asexual parasites at day 3, 7, 14, 28 and 42 after initiating study treatment.</description>
          <population>Full analysis set (FAS) – all subjects receiving at least one dose of study drug and who are confirmed to have P. falciparum malaria at baseline.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change of Parasite Count From Baseline at 24 Hours</title>
        <description>Percent change of parasite count from baseline at 24 hours</description>
        <time_frame>baseline, 24 hours</time_frame>
        <population>Full analysis set (FAS) – all subjects receiving at least one dose of study drug and who are confirmed to have P. falciparum malaria at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>One Artemether-lumefantrine (COA566) dispersible tablet taken orally twice a day during 3 days.
Infants age &gt;28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change of Parasite Count From Baseline at 24 Hours</title>
          <description>Percent change of parasite count from baseline at 24 hours</description>
          <population>Full analysis set (FAS) – all subjects receiving at least one dose of study drug and who are confirmed to have P. falciparum malaria at baseline.</population>
          <units>Percent Change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-99.4" spread="1.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Parasitaemia at 48 Hours After Treatment Initiation Greater Than at Baseline</title>
        <description>Number of participants with parasite density at 48 hours after treatment initiation greater than parasite density at baseline.</description>
        <time_frame>48 hours</time_frame>
        <population>Full analysis set (FAS) – all subjects receiving at least one dose of study drug and who are confirmed to have P. falciparum malaria at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>One Artemether-lumefantrine (COA566) dispersible tablet taken orally twice a day during 3 days.
Infants age &gt;28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Parasitaemia at 48 Hours After Treatment Initiation Greater Than at Baseline</title>
          <description>Number of participants with parasite density at 48 hours after treatment initiation greater than parasite density at baseline.</description>
          <population>Full analysis set (FAS) – all subjects receiving at least one dose of study drug and who are confirmed to have P. falciparum malaria at baseline.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Parasitaemia at 72 Hours After Treatment Initiation Greater Than or Equal to 25 Percent of Count at Baseline</title>
        <description>Number of participants with parasite density at 72 hours after treatment initiation greater than or equal to 25 percent of parasite density at baseline.</description>
        <time_frame>72 hours</time_frame>
        <population>Full analysis set (FAS) – all subjects receiving at least one dose of study drug and who are confirmed to have P. falciparum malaria at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>One Artemether-lumefantrine (COA566) dispersible tablet taken orally twice a day during 3 days.
Infants age &gt;28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Parasitaemia at 72 Hours After Treatment Initiation Greater Than or Equal to 25 Percent of Count at Baseline</title>
          <description>Number of participants with parasite density at 72 hours after treatment initiation greater than or equal to 25 percent of parasite density at baseline.</description>
          <population>Full analysis set (FAS) – all subjects receiving at least one dose of study drug and who are confirmed to have P. falciparum malaria at baseline.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Parasite Clearance (PCT)</title>
        <description>Time from first dose until first total and continued disappearance of asexual parasite forms which remains at least a further 48 hours.</description>
        <time_frame>Up to 7 days</time_frame>
        <population>Full analysis set (FAS) – all subjects receiving at least one dose of study drug and who are confirmed to have P. falciparum malaria at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>One Artemether-lumefantrine (COA566) dispersible tablet taken orally twice a day during 3 days.
Infants age &gt;28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Parasite Clearance (PCT)</title>
          <description>Time from first dose until first total and continued disappearance of asexual parasite forms which remains at least a further 48 hours.</description>
          <population>Full analysis set (FAS) – all subjects receiving at least one dose of study drug and who are confirmed to have P. falciparum malaria at baseline.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.1" spread="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Fever Clearance (FCT)</title>
        <description>Time from first dose to the first time the axillary body temperature decreased below and remained below 37.5° C for at least 48 hours.</description>
        <time_frame>Up to 7 days</time_frame>
        <population>Full analysis set (FAS) – all subjects receiving at least one dose of study drug and who are confirmed to have P. falciparum malaria at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>One Artemether-lumefantrine (COA566) dispersible tablet taken orally twice a day during 3 days.
Infants age &gt;28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Fever Clearance (FCT)</title>
          <description>Time from first dose to the first time the axillary body temperature decreased below and remained below 37.5° C for at least 48 hours.</description>
          <population>Full analysis set (FAS) – all subjects receiving at least one dose of study drug and who are confirmed to have P. falciparum malaria at baseline.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.02" spread="6.433"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Gametocyte Clearance (GCT)</title>
        <description>Time from first dose until first total and continued disappearance of gametocytes which remains at least a further 48 hours.</description>
        <time_frame>Up to 7 days</time_frame>
        <population>Full analysis set (FAS) – all subjects receiving at least one dose of study drug and who are confirmed to have P. falciparum malaria at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>One Artemether-lumefantrine (COA566) dispersible tablet taken orally twice a day during 3 days.
Infants age &gt;28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Gametocyte Clearance (GCT)</title>
          <description>Time from first dose until first total and continued disappearance of gametocytes which remains at least a further 48 hours.</description>
          <population>Full analysis set (FAS) – all subjects receiving at least one dose of study drug and who are confirmed to have P. falciparum malaria at baseline.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.32" spread="77.294"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Cohort 1</title>
          <description>One Artemether-lumefantrine (COA566) dispersible tablet taken orally twice a day during 3 days.
Infants age &gt;28 days.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 15.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cerebral malaria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 15.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Malaria</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Rash pustular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

